Ryvu Therapeutics S.A. (FRA:9Y4)

Ryvu Therapeutics Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	89.12	160.07	57.94	101.92	83.24	136.22
Short-Term Investments	47.43	65.86	175.73	0.53	4.99	24.97
Cash & Short-Term Investments	136.56	225.93	233.67	102.45	88.23	161.19
Cash Growth	-44.84%	-3.31%	128.09%	16.11%	-45.26%	123.54%
Accounts Receivable	6.69	15.66	9.19	1.05	5.94	2.2
Other Receivables	11.52	10.92	23.65	258.85	5.8	5.75
Receivables	18.21	26.58	32.84	259.89	11.74	7.95
Inventory	0.62	1.21	2.12	1.76	1.96	1.68
Prepaid Expenses	-	-	-	2.35	1.63	0.58
Other Current Assets	7.26	18.72	9.77	1.48	0.69	0.98
Total Current Assets	162.64	272.44	278.39	367.93	104.25	172.36
Property, Plant & Equipment	68.29	72.74	77.56	82.22	91.18	91.16
Long-Term Investments	6.43	16.77	34.37	20.48	29.4	29.12
Other Intangible Assets	7	8.12	6.34	4.28	3.04	2.32
Long-Term Deferred Tax Assets	-	-	-	-	0.33	0.59
Other Long-Term Assets	10.98	8.72	6.55	0.08	0.6	0.09
Total Assets	255.34	378.78	403.2	474.98	228.81	295.64
Accounts Payable	21.49	31.15	23.14	12.58	11.69	6.26
Accrued Expenses	7.84	12.28	12.22	11.7	4.86	5.31
Short-Term Debt	0.12	0.29	0.13	0.06	0.02	0
Current Portion of Long-Term Debt	16.48	25.79	-	0.81	0.81	0.81
Current Portion of Leases	0.46	0.5	0.41	1.03	1.92	2.27
Current Income Taxes Payable	-	-	-	-	5.46	-
Current Unearned Revenue	25.29	35.71	31.53	16.71	8.95	14.56
Other Current Liabilities	-0	2.21	2.27	1.93	2.5	4.6
Total Current Liabilities	71.67	107.93	69.7	44.81	36.2	33.81
Long-Term Debt	77.07	82.56	8.85	9.9	8.86	1.55
Long-Term Leases	1.06	1.39	0.37	0.87	1.58	2.77
Long-Term Unearned Revenue	34.02	42.74	64.26	75.8	20.26	27.5
Pension & Post-Retirement Benefits	0.28	0.28	0.43	0.14	0.12	0.23
Long-Term Deferred Tax Liabilities	0.02	-	-	-	0.44	6.04
Other Long-Term Liabilities	0	-	-	0.06	0.06	-
Total Liabilities	184.12	234.89	143.61	131.59	67.51	71.92
Common Stock	9.25	9.25	9.25	7.34	7.34	7.34
Additional Paid-In Capital	519.75	519.75	519.75	279.06	279.06	279.06
Retained Earnings	-195.08	-111.44	-0.01	92.1	175.88	261.54
Comprehensive Income & Other	-262.69	-273.67	-269.39	-35.12	-300.99	-324.22
Total Common Equity	71.22	143.88	259.59	343.39	161.3	223.72
Shareholders' Equity	71.22	143.88	259.59	343.39	161.3	223.72
Total Liabilities & Equity	255.34	378.78	403.2	474.98	228.81	295.64
Total Debt	95.19	110.53	9.76	12.67	13.19	7.41
Net Cash (Debt)	41.37	115.4	223.91	89.77	75.04	153.78
Net Cash Growth	-75.17%	-48.46%	149.42%	19.63%	-51.20%	144.52%
Net Cash Per Share	1.79	4.99	9.78	4.89	4.09	9.17
Filing Date Shares Outstanding	23.12	23.12	23.12	23.12	18.36	18.36
Total Common Shares Outstanding	23.12	23.12	23.12	23.12	18.36	18.36
Working Capital	90.97	164.51	208.69	323.12	68.05	138.55
Book Value Per Share	3.08	6.22	11.23	14.85	8.79	12.19
Tangible Book Value	64.23	135.77	253.26	339.11	158.26	221.4
Tangible Book Value Per Share	2.78	5.87	10.95	14.67	8.62	12.06
Land	-	7.47	7.47	7.47	7.47	7.47
Buildings	-	52.21	52.2	52.15	53	48.33
Machinery	-	16.09	15.38	14.15	13.8	13.11
Construction In Progress	-	0.35	-	-	0.61	4.58

Source: S&P Global Market Intelligence. Standard template. Financial Sources.